CorVel Corp
NASDAQ:CRVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (40.2), the stock would be worth $116.98 (109% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 19.2 | $55.93 |
0%
|
| 3-Year Average | 40.2 | $116.98 |
+109%
|
| 5-Year Average | 36.3 | $105.61 |
+89%
|
| Industry Average | 19.2 | $55.96 |
+0%
|
| Country Average | 19.6 | $57.05 |
+2%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
CorVel Corp
NASDAQ:CRVL
|
2.9B USD | 19.2 | 27.1 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD | 14.2 | 55.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
68.5B EUR | 10 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
73.7B USD | 0 | 12.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 16.8 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.9B EUR | 13.7 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.1B USD | 15.9 | 21.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.8B USD | 17.3 | 24.8 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 9.8 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.5B USD | -27.4 | -27.6 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 9.7 | 13.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
CorVel Corp
Glance View
In the intricate world of healthcare management, CorVel Corporation stands as a pivotal player, harmonizing technology and service to streamline the complexities of risk management and cost containment. Founded in 1987, CorVel has relentlessly pursued the mission of enhancing workplace injury claims processes, reducing expenses while ensuring quality care for the injured. The company's foundation is built on its ability to provide innovative solutions through advanced technology platforms that automate and optimize the management of workers’ compensation, liability claims, and healthcare services. By integrating data analytics, artificial intelligence, and cutting-edge claims management software, CorVel enables employers, insurers, and third-party administrators to keep a tight rein on costs and improve outcomes through proactive decision-making and efficient service delivery. CorVel’s revenue model is intricately tied to its suite of diversified services. The company generates income through its extensive offerings in network solutions, bill review, case management, and pharmacy benefit management. Network solutions form the backbone, providing clients with access to a broad network of medical providers while negotiating favorable rates. Meanwhile, their robust bill review system ensures that every medical claim is scrutinized for accuracy and compliance, a process that helps clients avoid overpayments and recover funds. Case management services further augment their revenue, as skilled professionals facilitate rehabilitation efforts, coordinate care, and monitor recovery progress to encourage cost savings. Moreover, the pharmacy benefit management branch secures additional profit by optimizing prescription costs and improving medication adherence. Together, these services create a seamless ecosystem where CorVel captures significant value through efficiency gains and cost control, solidifying its position in the competitive healthcare management landscape.